VOYA Investment Management
RCUS icon

VOYA Investment Management’s Arcus Biosciences RCUS Stock Holding History

VOYA Investment Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$530K Buy
17,201
+3,195
+23% +$79K ﹤0.01% 1794
2026
Q1 		$303K Buy
14,006
+615
+5% +$13.3K ﹤0.01% 1947
2025
Q4 		$319K Sell
13,391
-17,171
-56% -$350K ﹤0.01% 1945
2025
Q3 		$416K Sell
30,562
-15,220
-33% -$158K ﹤0.01% 1844
2025
Q2 		$373K Buy
45,782
+3,179
+7% +$27.2K ﹤0.01% 2030
2025
Q1 		$334K Buy
42,603
+17,929
+73% +$208K ﹤0.01% 2067
2024
Q4 		$367K Buy
24,674
+6,733
+38% +$110K ﹤0.01% 2089
2024
Q3 		$274K Sell
17,941
-399
-2% -$6.29K ﹤0.01% 2304
2024
Q2 		$279K Buy
18,340
+372
+2% +$6K ﹤0.01% 2283
2024
Q1 		$339K Sell
17,968
-13,653
-43% -$236K ﹤0.01% 2188
2023
Q4 		$604K Buy
31,621
+242
+0.8% +$3.87K ﹤0.01% 1968
2023
Q3 		$563K Buy
31,379
+268
+0.9% +$5.38K ﹤0.01% 1968
2023
Q2 		$632K Buy
31,111
+1,079
+4% +$20.5K ﹤0.01% 1947
2023
Q1 		$548K Buy
30,032
+953
+3% +$18.2K ﹤0.01% 1996
2022
Q4 		$601K Buy
29,079
+2,170
+8% +$59.7K ﹤0.01% 1923
2022
Q3 		$704K Buy
26,909
+2,151
+9% +$56.9K ﹤0.01% 1813
2022
Q2 		$627K Buy
24,758
+7,080
+40% +$173K ﹤0.01% 1696
2022
Q1 		$558K Hold
17,678
– – ﹤0.01% 1845
2021
Q4 		$715K Sell
17,678
-332
-2% -$12.9K ﹤0.01% 1777
2021
Q3 		$628K Hold
18,010
– – ﹤0.01% 1904
2021
Q2 		$494K Sell
18,010
-480
-3% -$13.7K ﹤0.01% 2093
2021
Q1 		$519K Buy
18,490
+61
+0.3% +$2.12K ﹤0.01% 2013
2020
Q4 		$478K Buy
18,429
+4,263
+30% +$103K ﹤0.01% 1950
2020
Q3 		$243K Buy
14,166
+2,710
+24% +$60.5K ﹤0.01% 2056
2020
Q2 		$283K Sell
11,456
-5,372
-32% -$145K ﹤0.01% 1996
2020
Q1 		$234K Hold
16,828
– – ﹤0.01% 2043
2019
Q4 		$170K Buy
16,828
+1,953
+13% +$16.4K ﹤0.01% 2426
2019
Q3 		$135K Hold
14,875
– – ﹤0.01% 2338
2019
Q2 		$118K Buy
14,875
+1,923
+15% +$19.3K ﹤0.01% 2424
2019
Q1 		$162K Hold
12,952
– – ﹤0.01% 2326
2018
Q4 		$139K Buy
+12,952
New +$151K ﹤0.01% 2329

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VOYA Investment Management's RCUS Position: Q2 2026 in Review

VOYA Investment Management increased its Arcus Biosciences (RCUS) stake by 23% in Q2 2026, buying an estimated $79K and bringing the position to 17,201 shares worth $530K. The position accounts for ﹤0.01% of the portfolio, ranked #1794.

VOYA Investment Management first reported a position in RCUS in Q4 2018 and has held it in 31 quarters since. The position peaked at $715K in Q4 2021. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • VOYA Investment Management held 17,201 shares of Arcus Biosciences worth $530K as of Q2 2026.
  • VOYA Investment Management bought 3,195 Arcus Biosciences shares in Q2 2026, an estimated $79K.
  • Arcus Biosciences made up ﹤0.01% of VOYA Investment Management's portfolio in Q2 2026, its #1794 holding.
  • VOYA Investment Management first reported a position in Arcus Biosciences in Q4 2018 and has held it in 31 quarters since.
  • VOYA Investment Management's Arcus Biosciences position peaked at $715K in Q4 2021.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.